title: Resumption of driving after life-threatening ventricular tachyarrhythmia.
abstract: BACKGROUND
  Although the privilege of driving must be respected, it may be necessary to restrict driving when it poses a threat to others. The risks associated with allowing patients with life-threatening ventricular tachyarrhythmias to drive have not been quantified.
  
  
  METHODS
  The Antiarrhythmics versus Implantable Defibrillators (AVID) trial compared antiarrhythmic-drug therapy with the implantation of defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. In the current study, we sent patients who participated in the AVID trial a questionnaire, to be completed anonymously, requesting information about driving habits and experiences.
  
  
  RESULTS
  The questionnaire was returned by 758 of 909 patients (83 percent). Of these, 627 patients drove during the year before their index episode of ventricular tachyarrhythmia. A total of 57 percent of these patients resumed driving within 3 months after randomization in the AVID trial, 78 percent within 6 months, and 88 percent within 12 months. While driving, 2 percent had a syncopal episode, 11 percent had dizziness or palpitations that necessitated stopping the vehicle, 22 percent had dizziness or palpitations that did not necessitate stopping the vehicle, and 8 percent of the 295 patients with an implantable cardioverter-defibrillator received a shock. Fifty patients reported having at least 1 accident, for a total of 55 accidents during 1619 patient-years of follow-up after the resumption of driving (3.4 percent per patient-year). Only 11 percent of these accidents were preceded by symptoms of possible arrhythmia (0.4 percent per patient-year).
  
  
  CONCLUSIONS
  Most patients with ventricular tachyarrhythmias resume driving early. Although it is common for them to have symptoms of possible arrhythmia while driving, accidents are uncommon and occur with a frequency that is lower than the annual accident rate of 7.1 percent in the general driving population of the United States.
authors.affiliation: University of Rochester Medical Center, NY, USA.
authors.forename: T
authors.initials: T
authors.lastname: Akiyama
authors.forename: J L
authors.initials: JL
authors.lastname: Powell
authors.forename: L B
authors.initials: LB
authors.lastname: Mitchell
authors.forename: F A
authors.initials: FA
authors.lastname: Ehlert
authors.forename: C
authors.initials: C
authors.lastname: Baessler
mesh_terms: D000063:Accidents, Traffic / Q000706:statistics & numerical data*; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000453:epidemiology; D001334:Automobile Driving / Q000706:statistics & numerical data; D017147:Defibrillators, Implantable; D004244:Dizziness / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D011795:Surveys and Questionnaires; D013575:Syncope / Q000453:epidemiology; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000628:therapy; D014481:United States
chemical_list: D000889:Anti-Arrhythmia Agents